Company Profile

TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc., develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care. Its product, the TearLab Osmolarity System, enables the measurement of tear osmolarity in the doctor's office. The TearLab Osmolarity System consists of approximately three components: the TearLab disposable, the TearLab Pen, and the TearLab Reader. The TearLab disposable is a single-use microfluidic microchip. The TearLab Pen is a hand-held device that interfaces with the TearLab disposable. The TearLab Reader is a small desktop unit that allows for the docking of the TearLab Pen.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

23/07/24	Bausch + Lomb Corporation acquired TearLab Corporation from Accelmed Partners and other shareholders for approximately $24 million.	CI
09/12/21	TearLab Corporation Announces Board Appointments	CI
09/12/21	TearLab Corporation Appoints Adam Szaronos as Chief Executive Officer	CI
09/11/21	Tearlab Corporation Appoints James V. Mazzo to the Company's Board of Directors	CI
16/09/21	MellingMedical and TearLab Agreement Aims to Enhance Early Detection of Dry Eye Disease in American Veterans	CI
28/07/20	TearLab Appoints Adam Szaronos as Chief Commercial Officer	CI
09/07/20	Accelmed Partners II, fund managed by Accelmed Fund (Accelmed Partners) completed the acquisition of TearLab Corporation.	CI
09/07/20	TearLab Corporation to Seek Acquisitions	CI
26/06/20	Tearlab Corporation Reports Earnings Results for the First Quarter Ended March 31, 2020	CI
11/05/20	TearLab Corporation Announces Board Appointments	CI
11/05/20	Tearlab Mulls Inorganic Growth Opportunities	CI
11/05/20	TearLab Corporation announced that it expects to receive $25 million in funding from Accelmed Fund	CI
11/05/20	Accelmed Partners II, fund managed by Accelmed Fund (Accelmed Partners) entered into term sheet to acquire TearLab Corporation for $0.74 million.	CI

09/07/20	TEARLAB CORP : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
26/06/20	TearLab: 1Q Earnings Snapshot	AQ
26/06/20	TEARLAB : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)	AQ
09/06/20	TEARLAB : Entry into a Material Definitive Agreement (form 8-K/A)	AQ
30/05/20	TEARLAB CORP : Entry into a Material Definitive Agreement (form 8-K)	AQ

Manager	Title	Age	Since
Adam Szaronos CEO	Chief Executive Officer	-	01/04/2026
Benjamin D. Sullivan CTO	Chief Tech/Sci/R&D Officer	-	17/07/2009
John Lund DFI	Director of Finance/CFO	60	01/07/2022

Director	Title	Age	Since
Uri Geiger BRD	Director/Board Member	58	09/07/2020
James V. Mazzo CHM	Chairman	68	09/12/2021
Richard Lindstrom BRD	Director/Board Member	78	01/09/2004

Date	Insider	Type	Main position	Quantity	% Market Cap.
7/9/20 A	Joseph S. Jensen	Tender	Chief Executive Officer	29,206	0.1196%
7/9/20 A	Michael Marquez	Tender	Chief Financial Officer	500	0.0020%
7/9/20 A	Paul M. Karpecki	Tender	Director	102,200	0.4187%

TearLab Corporation Stock

Stocks

Medical Equipment, Supplies & Distribution

Latest news : TearLab Corporation

Press Releases: TearLab Corporation

Managers and Directors: TearLab Corporation

Latest insider transactions

Glasses, Spectacles & Contact Lenses

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TEARLAB CORPORATION	-.--%	+2.84%	-	-	1.41M
ESSILORLUXOTTICA	+1.24%	+0.40%	-40.00%	-7.57%	87.56B
ALCON INC.	-0.81%	-3.10%	-10.64%	-20.65%	35.46B
THE COOPER COMPANIES, INC.	+0.08%	+0.07%	+1.33%	-17.64%	14.87B
LENSKART SOLUTIONS LIMITED	+1.01%	+8.10%	-	-	12.02B
SHANGHAI CONANT OPTICAL CO., LTD.	+1.22%	+4.44%	-14.91%	+692.86%	2.47B
AUTEK CHINA INC.	-3.25%	-4.60%	-43.24%	-59.03%	1.46B
PEGAVISION CORPORATION	-0.53%	+0.81%	+17.54%	+7.83%	897M
MENICON CO., LTD.	-1.08%	-2.34%	+55.84%	-5.19%	897M
SPYGLASS PHARMA, INC.	+1.07%	+1.18%	-	-	887M
Average	-0.11%	+0.73%	-4.87%	+84.37%	17.39B
Weighted average by Cap.	+0.58%	+0.19%	-27.12%	-0.22%